(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.
The three biggest winners today are SPADEL, LAVIDE HOLDING, and BENEVOLENTAI.
| Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|
| SPADEL (SPA.BR) | 198.00 | 8.2% | 2024-08-20 12:21:36 |
| LAVIDE HOLDING (LVIDE.AS) | 0.27 | 8.13% | 2024-08-20 12:02:52 |
| BENEVOLENTAI (BAI.AS) | 0.59 | 7.27% | 2024-08-20 12:00:55 |
| TEKNA HOLDING (TEKNA.OL) | 5.80 | 5.45% | 2024-08-20 12:44:08 |
| NEKKAR (NKR.OL) | 11.35 | 5.09% | 2024-08-20 12:41:22 |
| TEIXEIRA DUARTE (TDSA.LS) | 0.10 | 4.8% | 2024-08-20 12:24:04 |
| ITERA (ITERA.OL) | 11.70 | 3.54% | 2024-08-20 12:40:40 |
| PEXIP HOLDING (PEXIP.OL) | 34.70 | 3.43% | 2024-08-20 12:42:30 |
| SEQUANA MEDICAL (SEQUA.BR) | 1.09 | 3.33% | 2024-08-20 12:21:23 |
| VIVORYON (VVY.AS) | 2.32 | 3.11% | 2024-08-20 12:04:35 |
The three biggest losers today are CELYAD ONCOLOGY, SALMONES CAMANCHAC, and ARCTICZYMES TECHNO.
| Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|
| CELYAD ONCOLOGY (CYAD.BR) | 0.21 | -17.67% | 2024-08-20 12:05:38 |
| SALMONES CAMANCHAC (SACAM.OL) | 16.30 | -11.89% | 2024-08-20 12:42:59 |
| ARCTICZYMES TECHNO (AZT.OL) | 21.20 | -9.79% | 2024-08-20 12:24:46 |
| HYLORIS (HYL.BR) | 6.10 | -9.23% | 2024-08-20 12:20:11 |
| ATLANTIC SAPPHIRE (ASA.OL) | 4.49 | -8.7% | 2024-08-20 12:24:55 |
| AKVA GROUP (AKVA.OL) | 62.20 | -7.99% | 2024-08-20 12:24:41 |
| ARRIBATEC GROUP (ARR.OL) | 3.13 | -7.67% | 2024-08-20 12:24:50 |
| SALMAR (SALM.OL) | 595.00 | -6.82% | 2024-08-20 12:42:56 |
| IDEX BIOMETRICS (IDEX.OL) | 0.71 | -6.38% | 2024-08-20 12:40:36 |
| NEXT BIOMETRICS GP (NEXT.OL) | 7.88 | -6.19% | 2024-08-20 12:41:26 |
Winners today
1. SPADEL (SPA.BR)
8.2% Price Change
Spadel SA produces and markets natural mineral water in Belgium. It offers natural mineral water under the Spa, Bru, Wattwiller, Carola, and Devin brand names. The company is based in Woluwe-Saint-Lambert, Belgium. Spadel SA operates as a subsidiary of Finances Et Industries Sa.
BEL 20 ended the session with SPADEL jumping 8.2% to €198.00 on Tuesday, after five sequential sessions in a row of losses. BEL 20 dropped 0.4% to €4,068.22, following the last session’s upward trend on what was a somewhat down trend exchanging session today.
Earnings Per Share
As for profitability, SPADEL has a trailing twelve months EPS of €6.81.
PE Ratio
SPADEL has a trailing twelve months price to earnings ratio of 29.07. Meaning, the purchaser of the share is investing €29.07 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.52%.
Moving Average
SPADEL’s worth is way higher than its 50-day moving average of €170.68 and way higher than its 200-day moving average of €160.06.
Revenue Growth
Year-on-year quarterly revenue growth grew by 2.6%, now sitting on 345.94M for the twelve trailing months.
More news about SPADEL.
2. LAVIDE HOLDING (LVIDE.AS)
8.13% Price Change
Lavide Holding N.V. does not have significant operations. Previously, it was engaged in the provision of integrated information technology solutions for medium to large-sized companies and organizations. The company was formerly known as Qurius N.V. and changed its name to Lavide Holding N.V. in July 2013. Lavide Holding N.V. is based in Amsterdam, the Netherlands.
AEX-Index ended the session with LAVIDE HOLDING rising 8.13% to €0.27 on Tuesday, after two sequential sessions in a row of losses. AEX-Index dropped 0.64% to €903.04, following the last session’s upward trend on what was a somewhat negative trend exchanging session today.
Earnings Per Share
As for profitability, LAVIDE HOLDING has a trailing twelve months EPS of €-0.02.
More news about LAVIDE HOLDING.
3. BENEVOLENTAI (BAI.AS)
7.27% Price Change
BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company's development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the potential treatment of ALS; and various candidates for the treatment of fibrosis and Parkinson's disease. It has collaboration agreements with AstraZeneca and Merck to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.
AEX-Index ended the session with BENEVOLENTAI rising 7.27% to €0.59 on Tuesday while AEX-Index dropped 0.64% to €903.04.
Earnings Per Share
As for profitability, BENEVOLENTAI has a trailing twelve months EPS of €-0.63.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -51.01%.
Moving Average
BENEVOLENTAI’s worth is higher than its 50-day moving average of €0.57 and way under its 200-day moving average of €0.68.
Revenue Growth
Year-on-year quarterly revenue growth declined by 64.4%, now sitting on 7.33M for the twelve trailing months.
Yearly Top and Bottom Value
BENEVOLENTAI’s stock is valued at €0.59 at 22:40 EST, way below its 52-week high of €2.66 and way higher than its 52-week low of €0.46.
More news about BENEVOLENTAI.
4. TEKNA HOLDING (TEKNA.OL)
5.45% Price Change
Tekna Holding ASA engages in the development, manufacture, and sale of micron and nano powders, and plasma process solutions in North America, Europe, Asia, and internationally. The company offers spherical powders, such as titanium, nickel, and aluminum alloys, as well as tungsten and tantalum; and nanopowders, including nickel, silicon, and copper nanopowders, as well as boron nitride nanotubes for use in additive manufacturing, metal injection molding, thermal spray, and hot isostatic pressing. It serves aviation, aerospace, medical, mining and drilling, energy storage, and microelectronics industries. The company was founded in 1990 and is headquartered in Sherbrooke, Canada. Tekna Holding ASA is a subsidiary of Arendals Fossekompani ASA.
Oslo Børs Benchmark Index_GI ended the session with TEKNA HOLDING rising 5.45% to €5.80 on Tuesday, after five sequential sessions in a row of losses. Oslo Børs Benchmark Index_GI dropped 1.37% to €1,428.69, after five successive sessions in a row of gains, on what was an all-around negative trend trading session today.
Earnings Per Share
As for profitability, TEKNA HOLDING has a trailing twelve months EPS of kr-1.09.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -38.02%.
Moving Average
TEKNA HOLDING’s worth is above its 50-day moving average of kr5.42 and way under its 200-day moving average of kr6.94.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, TEKNA HOLDING’s stock is considered to be overbought (>=80).
Volatility
TEKNA HOLDING’s last week, last month’s, and last quarter’s current intraday variation average was a negative 5.08%, a negative 0.05%, and a positive 4.03%.
TEKNA HOLDING’s highest amplitude of average volatility was 5.08% (last week), 4.44% (last month), and 4.03% (last quarter).
More news about TEKNA HOLDING.
5. NEKKAR (NKR.OL)
5.09% Price Change
Nekkar ASA provides technologies, software, and automation solutions to offshore energy, renewables, and aquaculture industries. It operates through Syncrolift, Intellilift, and Techano Oceanlift segments. The company offers shipyard solutions, including shiplifting systems for launching and retrievals of vessels, and transfer systems for moving vessels around the yard; FastDocking products for efficient operations during docking and maintenance of vessels; and service and upgrades on shiplift and transfer systems, maintenance, spare replacements, and upgrades of small and larger components. In addition, the company offers load handling and lifting equipment, such as cranes, gangways, and fish transfer systems for the aquaculture and offshore energy industry; FiiZK closed cage solutions to avoid sea lice and enables waste collection from the harvest process; and SkyWalker, a wind turbine installation tool. Further, it develops industrial software solutions for digitalizing workflows through automation and remotely-controlled systems for drilling and offshore load handling. The company operates in Europe, Asia, Australia, New Zealand, North America, the United Arab Emirates, Africa, the United States, South America, India, Norway, and internationally. The company was formerly known as TTS Group ASA and changed its name to Nekkar ASA in July 2019. Nekkar ASA founded in 1966 and is headquartered in Kristiansand, Norway.
Oslo Børs Benchmark Index_GI ended the session with NEKKAR jumping 5.09% to €11.35 on Tuesday, after five successive sessions in a row of losses. Oslo Børs Benchmark Index_GI slid 1.37% to €1,428.69, after five successive sessions in a row of gains, on what was an all-around bearish trend exchanging session today.
Earnings Per Share
As for profitability, NEKKAR has a trailing twelve months EPS of kr0.76.
PE Ratio
NEKKAR has a trailing twelve months price to earnings ratio of 14.93. Meaning, the purchaser of the share is investing kr14.93 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.49%.
Moving Average
NEKKAR’s value is above its 50-day moving average of kr10.68 and way higher than its 200-day moving average of kr9.73.
More news about NEKKAR.
6. TEIXEIRA DUARTE (TDSA.LS)
4.8% Price Change
Teixeira Duarte, S.A. operates in the construction, concessions and services, real estate, hospitality, distribution, and automotive sectors in Portugal and internationally. The company is involved in the various construction activities, including geotechnical engineering and rehabilitation, buildings, infrastructures, and metalworking, as well as underground, railway, and maritime works; and the provision of concessions and services in various business areas, such as facilities management, facilities services, environment, and education. It also develops real estate properties; and operates hotels in Angola, Mozambique and Portugal. In addition, the company distributes food products through MAXI grocery stores; operates restaurants under the Pastelarias Nilo name; offers pharmacy products through Farmácia Popular stores; provides furniture and decoration products under the Dakaza brand; and distributes and integrates FMCG brands. Further, it sells light and heavy-duty cars, motorcycles, and equipment; and provides technical assistance. Teixeira Duarte, S.A. was founded in 1921 and is headquartered in Oeiras, Portugal.
PSI ended the session with TEIXEIRA DUARTE rising 4.8% to €0.10 on Tuesday while PSI fell 0.68% to €6,678.04.
Earnings Per Share
As for profitability, TEIXEIRA DUARTE has a trailing twelve months EPS of €-0.03.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -7.08%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, TEIXEIRA DUARTE’s stock is considered to be oversold (<=20).
Volume
Today’s last reported volume for TEIXEIRA DUARTE is 198000 which is 38.06% below its average volume of 319710.
Revenue Growth
Year-on-year quarterly revenue growth grew by 60.7%, now sitting on 842.11M for the twelve trailing months.
More news about TEIXEIRA DUARTE.
7. ITERA (ITERA.OL)
3.54% Price Change
Itera ASA, together with its subsidiaries, develops and operates digital solutions for businesses and organizations in Norway, Sweden, Ukraine, Denmark, Czech Republic, Iceland, Poland, and Slovakia. It offers data, artificial intelligence and analytics, development and architecture, test and quality assurance solutions, as well as cloud and application services. The company provides a range of services in the strategy and consulting, customer experience, and technology and cloud transformation areas. It serves banking and insurance, energy and utilities, industry and manufacturing, health and public services, technology and communication, and products and retail industries. The company was founded in 1989 and is headquartered in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with ITERA jumping 3.54% to €11.70 on Tuesday, after two consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI slid 1.37% to €1,428.69, after five sequential sessions in a row of gains, on what was an all-around down trend trading session today.
Earnings Per Share
As for profitability, ITERA has a trailing twelve months EPS of kr0.59.
PE Ratio
ITERA has a trailing twelve months price to earnings ratio of 19.83. Meaning, the purchaser of the share is investing kr19.83 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 63.44%.
Yearly Top and Bottom Value
ITERA’s stock is valued at kr11.70 at 22:40 EST, way below its 52-week high of kr15.70 and way above its 52-week low of kr10.50.
Moving Average
ITERA’s worth is above its 50-day moving average of kr11.44 and below its 200-day moving average of kr11.82.
Revenue Growth
Year-on-year quarterly revenue growth declined by 0.8%, now sitting on 869.77M for the twelve trailing months.
Sales Growth
ITERA’s sales growth for the current quarter is 3.4%.
More news about ITERA.
8. PEXIP HOLDING (PEXIP.OL)
3.43% Price Change
Pexip Holding ASA, a video technology company, provides end-to-end video conferencing platform and digital infrastructure worldwide. It offers self-hosted software application and as-a-service deployment options for enterprise video conferencing, built on its proprietary Infinity technology. The company also enables any meeting room device, such as Cisco Webex, HP/Poly, and Microsoft Teams Rooms to connect to any meeting technology, including Meet, Teams, and Zoom in the Connected Spaces solutions area as an interoperability provider. It serves government, public sector, healthcare, judicial, finance, military, and defense sectors. The company was founded in 2011 and is headquartered in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with PEXIP HOLDING jumping 3.43% to €34.70 on Tuesday while Oslo Børs Benchmark Index_GI slid 1.37% to €1,428.69.
Earnings Per Share
As for profitability, PEXIP HOLDING has a trailing twelve months EPS of kr-0.32.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -3.47%.
More news about PEXIP HOLDING.
9. SEQUANA MEDICAL (SEQUA.BR)
3.33% Price Change
Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, Switzerland, and internationally. The company products pipeline comprises alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body and heart failure. Sequana Medical NV was founded in 2006 and is headquartered in Ghent, Belgium.
BEL 20 ended the session with SEQUANA MEDICAL rising 3.33% to €1.09 on Tuesday, following the last session’s upward trend. BEL 20 fell 0.4% to €4,068.22, following the last session’s upward trend on what was a somewhat down trend exchanging session today.
Earnings Per Share
As for profitability, SEQUANA MEDICAL has a trailing twelve months EPS of €-1.22.
More news about SEQUANA MEDICAL.
10. VIVORYON (VVY.AS)
3.11% Price Change
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.
AEX-Index ended the session with VIVORYON jumping 3.11% to €2.32 on Tuesday while AEX-Index fell 0.64% to €903.04.
Earnings Per Share
As for profitability, VIVORYON has a trailing twelve months EPS of €-1.12.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -107.38%.
Volatility
VIVORYON’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.85%, a negative 0.01%, and a positive 7.52%.
VIVORYON’s highest amplitude of average volatility was 3.27% (last week), 3.26% (last month), and 7.52% (last quarter).
Volume
Today’s last reported volume for VIVORYON is 159899 which is 85.11% below its average volume of 1074080.
More news about VIVORYON.
Losers Today
1. CELYAD ONCOLOGY (CYAD.BR)
-17.67% Price Change
Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery/PerkinElmer for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
BEL 20 ended the session with CELYAD ONCOLOGY falling 17.67% to €0.21 on Tuesday, after three consecutive sessions in a row of gains. BEL 20 dropped 0.4% to €4,068.22, following the last session’s upward trend on what was a somewhat down trend trading session today.
Earnings Per Share
As for profitability, CELYAD ONCOLOGY has a trailing twelve months EPS of €-1.36.
Volatility
CELYAD ONCOLOGY’s last week, last month’s, and last quarter’s current intraday variation average was a positive 2.46%, a negative 0.14%, and a positive 3.06%.
CELYAD ONCOLOGY’s highest amplitude of average volatility was 2.89% (last week), 3.16% (last month), and 3.06% (last quarter).
Volume
Today’s last reported volume for CELYAD ONCOLOGY is 23672 which is 71.77% above its average volume of 13781.
More news about CELYAD ONCOLOGY.
2. SALMONES CAMANCHAC (SACAM.OL)
-11.89% Price Change
Salmones Camanchaca S.A. engages in the salmon farming business in Chile. The company offers Atlantic and Coho salmon products in various formats, such as whole, fillet, portion, and other products including bits and pieces, harasu, and scrape meat. It also exports its products. Salmones Camanchaca S.A. was incorporated in 2009 and is based in Puerto Montt, Chile. Salmones Camanchaca S.A. (SNSE:SALMOCAM) operates as a subsidiary of Camanchaca S.A. (SNSE:CAMANCHACA).
Oslo Børs Benchmark Index_GI ended the session with SALMONES CAMANCHAC falling 11.89% to €16.30 on Tuesday, after two sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI fell 1.37% to €1,428.69, after five successive sessions in a row of gains, on what was an all-around negative trend exchanging session today.
Earnings Per Share
As for profitability, SALMONES CAMANCHAC has a trailing twelve months EPS of kr-0.87.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -7.32%.
More news about SALMONES CAMANCHAC.
3. ARCTICZYMES TECHNO (AZT.OL)
-9.79% Price Change
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing in Norway, Germany, Lithuania, France, Italy, rest of Europe, the United States, and internationally. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; double-strand specific DNases and derived kits for the removal of double stranded DNA; DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. It serves the molecular tools research and diagnostics, and biomanufacturing markets. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.
Oslo Børs Benchmark Index_GI ended the session with ARCTICZYMES TECHNO sliding 9.79% to €21.20 on Tuesday while Oslo Børs Benchmark Index_GI dropped 1.37% to €1,428.69.
Earnings Per Share
As for profitability, ARCTICZYMES TECHNO has a trailing twelve months EPS of kr0.34.
PE Ratio
ARCTICZYMES TECHNO has a trailing twelve months price to earnings ratio of 62.35. Meaning, the purchaser of the share is investing kr62.35 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.15%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
ARCTICZYMES TECHNO’s EBITDA is 12.21.
More news about ARCTICZYMES TECHNO.
4. HYLORIS (HYL.BR)
-9.23% Price Change
BEL 20 ended the session with HYLORIS sliding 9.23% to €6.10 on Tuesday while BEL 20 fell 0.4% to €4,068.22.
Earnings Per Share
As for profitability, HYLORIS has a trailing twelve months EPS of €-0.56.
Volatility
HYLORIS’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.01%, a positive 3.17%, and a positive 12.83%.
HYLORIS’s highest amplitude of average volatility was 5.83% (last week), 12.83% (last month), and 12.83% (last quarter).
More news about HYLORIS.
5. ATLANTIC SAPPHIRE (ASA.OL)
-8.7% Price Change
Atlantic Sapphire ASA, together with its subsidiaries, engages in the production and sale of land-based salmon in Denmark and the United States. The company was incorporated in 2010 and is headquartered in Vikebukt, Norway.
Oslo Børs Benchmark Index_GI ended the session with ATLANTIC SAPPHIRE falling 8.7% to €4.49 on Tuesday while Oslo Børs Benchmark Index_GI fell 1.37% to €1,428.69.
Earnings Per Share
As for profitability, ATLANTIC SAPPHIRE has a trailing twelve months EPS of kr-37.38.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.26%.
Yearly Top and Bottom Value
ATLANTIC SAPPHIRE’s stock is valued at kr4.49 at 22:40 EST, under its 52-week low of kr4.50.
Volatility
ATLANTIC SAPPHIRE’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.55%, a positive 0.23%, and a positive 5.01%.
ATLANTIC SAPPHIRE’s highest amplitude of average volatility was 3.16% (last week), 5.63% (last month), and 5.01% (last quarter).
More news about ATLANTIC SAPPHIRE.
6. AKVA GROUP (AKVA.OL)
-7.99% Price Change
AKVA group ASA designs, purchases, manufactures, assembles, sells, and installs technology products; and provides rental and consulting services for the aquaculture industry. The company operates through three segments: Sea Based Technology (SBT), Digital, and Land Based Technology (LBT). The SBT segment offers feed barges, steel cages, fish farming cages, feed systems, polyethylene (PE) cages, nets, sensors, cameras, light systems, net cleaning systems, remotely operating vehicles, and mooring systems under the Polarcirkel, Wavemaster, and AKVASmart brands. This segment also provides PE-boats for the fish-farming, diving, and the oil and gas service industries. The Digital segment provides production control, planning, traceability, and ERP software for the aquaculture and fishing industries under the Fishtalk, AKVAconnect, AKVA Submerged, and AKVA Observe names. The LBT segment designs and delivers recirculation systems for land-based fish farming, as well as provides water quality conditions for fresh and seawater operations. AKVA group ASA operates in Norway, Chile, the United Kingdom, Denmark, Canada, and internationally. The company was incorporated in 1982 and is based in Klepp Stasjon, Norway. AKVA group ASA is a subsidiary of Egersund Group AS.
Oslo Børs Benchmark Index_GI ended the session with AKVA GROUP falling 7.99% to €62.20 on Tuesday while Oslo Børs Benchmark Index_GI dropped 1.37% to €1,428.69.
Earnings Per Share
As for profitability, AKVA GROUP has a trailing twelve months EPS of kr-0.2.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -8.75%.
Moving Average
AKVA GROUP’s worth is under its 50-day moving average of kr63.44 and above its 200-day moving average of kr59.81.
More news about AKVA GROUP.
7. ARRIBATEC GROUP (ARR.OL)
-7.67% Price Change
Arribatec Group ASA, a software and consulting company, provides digital business solutions in Norway, Europe, the Americas, and internationally. The company offers solutions for businesses, including ERP systems, integrations, consulting, health checks, develops, HR and payroll, financial and project planning, bank solutions, and travel and expenses. Its solutions include QualiWare, a management system that structures and visualizes processes, activities, regulations, and requirements; Unit4 solutions; RamBase, an ERP business solution that gives control over the value chain; Power BI solutions; Hypergene, a business management tool; Adra Suite that integrates with other financial systems; Microsoft 365; CatalystOne; and Pagero that ensures compliance with legal and electronic billing requirements. Arribatec Group ASA was incorporated in 1998 and is headquartered in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with ARRIBATEC GROUP dropping 7.67% to €3.13 on Tuesday while Oslo Børs Benchmark Index_GI slid 1.37% to €1,428.69.
Earnings Per Share
As for profitability, ARRIBATEC GROUP has a trailing twelve months EPS of kr-0.48.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -17.94%.
Yearly Top and Bottom Value
ARRIBATEC GROUP’s stock is valued at kr3.13 at 22:40 EST, way under its 52-week high of kr6.81 and way above its 52-week low of kr0.30.
Volatility
ARRIBATEC GROUP’s last week, last month’s, and last quarter’s current intraday variation average was a negative 5.78%, a negative 1.47%, and a positive 2.96%.
ARRIBATEC GROUP’s highest amplitude of average volatility was 6.73% (last week), 4.18% (last month), and 2.96% (last quarter).
Revenue Growth
Year-on-year quarterly revenue growth grew by 23.2%, now sitting on 557M for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ARRIBATEC GROUP’s stock is considered to be overbought (>=80).
More news about ARRIBATEC GROUP.
8. SALMAR (SALM.OL)
-6.82% Price Change
SalMar ASA, an aquaculture company, produces and sells farmed salmon in Asia, North America, Europe, and internationally. The company operates through Fish Farming Central Norway, Fish Farming Northern Norway, Icelandic Salmon, Sales & Industry, and SalMar Aker Ocean segments. It is involved in the broodstock, harvesting, processing, and smolt production activities. In addition, the company offers fish fillets and related products. SalMar ASA was founded in 1991 and is headquartered in Kverva, Norway.
Oslo Børs Benchmark Index_GI ended the session with SALMAR sliding 6.82% to €595.00 on Tuesday while Oslo Børs Benchmark Index_GI dropped 1.37% to €1,428.69.
Earnings Per Share
As for profitability, SALMAR has a trailing twelve months EPS of kr13.15.
PE Ratio
SALMAR has a trailing twelve months price to earnings ratio of 45.25. Meaning, the purchaser of the share is investing kr45.25 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.71%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 272.3% and 45.3%, respectively.
More news about SALMAR.
9. IDEX BIOMETRICS (IDEX.OL)
-6.38% Price Change
IDEX Biometrics ASA, together with its subsidiaries, designs, develops, and sells fingerprint authentication solutions in Norway, Europe, the Middle East, Africa, the Americas, and the Asia-Pacific regions. The company's fingerprint authentication solutions are used primarily in contactless smart cards, that includes financial payment and access control cards, as well as card-based devices for the storage of digital currencies. It primarily serves smart card manufacturers and similar solution integrators. The company was incorporated in 1996 and is headquartered in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with IDEX BIOMETRICS dropping 6.38% to €0.71 on Tuesday while Oslo Børs Benchmark Index_GI slid 1.37% to €1,428.69.
Earnings Per Share
As for profitability, IDEX BIOMETRICS has a trailing twelve months EPS of kr-1.07.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -223.25%.
More news about IDEX BIOMETRICS.
10. NEXT BIOMETRICS GP (NEXT.OL)
-6.19% Price Change
NEXT Biometrics Group ASA, together with its subsidiaries, provides fingerprint sensor technology in Asia, Europe, Africa, and North America. The company offers fingerprint sensor modules and readers, flexible biometric subassemblies, and face recognition software, as well as software and hardware development kits. It also sells its products to office and notebooks; payment and fintech; access control; and public security sectors. The company sells its sensors to distributors and original equipment manufacturer of electronic components. NEXT Biometrics Group ASA was founded in 2000 and is headquartered in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with NEXT BIOMETRICS GP dropping 6.19% to €7.88 on Tuesday while Oslo Børs Benchmark Index_GI fell 1.37% to €1,428.69.
Earnings Per Share
As for profitability, NEXT BIOMETRICS GP has a trailing twelve months EPS of kr-0.68.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -78.69%.
Yearly Top and Bottom Value
NEXT BIOMETRICS GP’s stock is valued at kr7.88 at 22:40 EST, way below its 52-week high of kr9.32 and way above its 52-week low of kr4.65.
More news about NEXT BIOMETRICS GP.
Stay up to date with our winners and losers daily report
